MYEG Services Berhad (MYEG) has entered a cooperation with Anhui Zhifei Longcom Biopharmaceutical Co Ltd (Zhifei) to get halal certification for the Chinese biopharma company’s Covid-19 vaccine.
The co-operation will also allow MYEG to exclusively distribute the vaccine in Malaysia for a 3-year period.
MYEG said in a recent statement that the two companies have signed an MOU, agreeing to cooperate in conducting Phase 3 clinical trials of Zhifei’s vaccine in Malaysia and complying to halal status requirements to secure halal certification from the Department of Islamic Development Malaysia (JAKIM).
“JAKIM’s halal accreditation will ensure increased acceptance of the vaccine among the global Muslim population,
The commencement of Phase 3 trial will make Zhifei’s vaccine one of the first to undergo this final stage trial in Malaysia under the purview of the Ministry of Health,” MYEG said.
Zhifei is a subsidiary of Chongqing Zhifei Biological Products Co Ltd and is listed on the Shenzhen Stock Exchange. It has been engaged in the biological products industry since 2002, mainly the production of vaccines for human use.
Zhifei is currently one of five Chinese companies conducting Phase 3 clinical trials of their Covid-19 vaccines in various parts of the world.
Upon successful completion of the Phase 3 trials, MYEG will be the sole distributor of the vaccine in Malaysia.
